Myriad Gains Exclusive Ovarian Cancer Test Niche with FDA Approval
Event summary
- Myriad Genetics received FDA approval for its MyChoice CDx Test as a companion diagnostic for GSK’s Zejula (niraparib) for advanced ovarian cancer.
- The approval is based on data from the PRIMA trial, which used the MyChoice CDx Test to stratify patients based on homologous recombination deficiency (HRD) status.
- The MyChoice CDx Test is the only FDA-approved companion diagnostic in the U.S. to identify HRD-positive patients eligible for Zejula treatment.
- Approximately 50% of patients with advanced ovarian cancer have HRD-positive tumors, representing a significant potential patient population.
The big picture
This approval establishes Myriad as a key player in the rapidly expanding precision oncology diagnostics market, capitalizing on the growing trend towards personalized cancer treatment. The exclusivity granted by the FDA approval provides a valuable competitive advantage, but the long-term success hinges on demonstrating clinical utility and securing favorable reimbursement. The PARP inhibitor market, while promising, is also facing increasing scrutiny regarding efficacy and patient selection, which could impact the demand for companion diagnostics.
What we're watching
- Market Adoption
- The speed of adoption by oncologists and hospitals will determine the initial revenue impact, as broader use requires education and integration into treatment protocols.
- Competitive Landscape
- While currently exclusive, the emergence of competing HRD tests could erode Myriad’s market share, particularly if they offer a more cost-effective or comprehensive analysis.
- Reimbursement
- Securing favorable reimbursement rates from payers will be critical for sustained growth, and any challenges in this area could limit patient access and test utilization.
Related topics